🇺🇸 FDA
Pipeline program

Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors

AMBER

Phase 1 other active

Quick answer

Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors for Patients with Advanced Solid Tumors is a Phase 1 program (other) at TESARO Bio Netherlands B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
TESARO Bio Netherlands B.V.
Indication
Patients with Advanced Solid Tumors
Phase
Phase 1
Modality
other
Status
active

Clinical trials